EBIT: Income before interest and taxes.
Immunovant, Inc. (IMVT) had EBIT of $-160.32M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-153.22M |
|
-- |
|
-- |
|
$160.32M |
|
$-160.32M |
|
$7.10M |
|
$-153.22M |
|
$-153.22M |
|
$-153.22M |
|
$-153.22M |
|
$-153.22M |
|
$-153.22M |
|
|
EBIT |
$-160.32M |
$-160.23M |
|
205.54M |
|
205.54M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$851.18M |
|
$0.35M |
|
$1.31M |
|
$852.49M |
|
$117.10M |
|
-- |
|
-- |
|
$117.10M |
|
$735.39M |
|
$735.39M |
|
$735.39M |
|
206.26M |
|
| Cash Flow Statement Financials | |
$-124.41M |
|
-- |
|
$20.10M |
|
$902.11M |
|
$797.80M |
|
$-104.31M |
|
$13.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-124.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.84% |
|
-20.84% |
|
-17.97% |
|
-20.84% |
|
$3.57 |
|
$-0.61 |
|
$-0.61 |
|